Path to Market Strategy From early phase, to patients

Designing and evaluating alternative paths to approval, reimbursement and commercial success.

From early phase, to patients

Path-to-Market strategy is about options: choices for how to take a molecule to market, optimising for clinical, regulatory and commercial hurdles.

You need a way to generate path to market choices, and a way to decide between them. That's where we come in.

There is a window of opportunity to differentiate by design

Delivering our Path to Market service.

The methodology, the discipline of making choices about Path to Market.

1 Deep insight on the talents of your molecule, creativity to challenge the 'obvious'

2 Create a longlist of differentiating path to market ideas

3 Methodology to generate a robust shortlist

4 Conduct external pressure testing of the choices

5 Decisioning

Path to market insights and innovation.

You can't develop tomorrow's medicines with yesterday's thinking.

From the blog
See all

A look into the metrics behind the Pharmaceutical Innovation and Invention Index

IDEA Pharma’s Pharmaceutical Invention and Innovation Index has become an industry standard in annually ranking the industry’s top ~30 companies in their ability to develop meaningful novel treatments, as well as commercializing them successfully

Read article
Latest podcast
See all

IDEA Podcast with Mike Rea